Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Phys Biol ; 9(2): 026001, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22473129

RESUMO

The P2X7 receptor (P2X7R) induces ionotropic Ca²âº signalling in different cell types. It plays an important role in the immune response and in the nervous system. Here, the mechanisms underlying intracellular Ca²âº variations evoked by 3'-O-(4-benzoyl)benzoyl-ATP (BzATP), a potent agonist of the P2X7R, in transfected HEK293 cells, are investigated both experimentally and theoretically. We propose a minimal model of P2X7R that is capable of reproducing, qualitatively and quantitatively, the experimental data. This approach was also adopted for the P2X7R variant, which lacks the entire C-terminus tail (trP2X7R). Then we introduce a biophysical model describing the Ca²âº dynamics in HEK293. Our model gives an account of the ionotropic Ca²âº influx evoked by BzATP on the basis of the kinetics model of P2X7R. To explain the complex Ca²âº responses evoked by BzATP, the model predicted that an impairment in Ca²âº extrusion flux through the plasma membrane is a key factor for Ca²âº homeostasis in HEK293 cells.


Assuntos
Sinalização do Cálcio/efeitos dos fármacos , Cálcio/metabolismo , Receptores Purinérgicos P2X7/química , Receptores Purinérgicos P2X7/metabolismo , Trifosfato de Adenosina/análogos & derivados , Trifosfato de Adenosina/farmacologia , Animais , Membrana Celular/efeitos dos fármacos , Células HEK293 , Humanos , Magnésio/metabolismo , Modelos Biológicos , Ratos , Transfecção
2.
Clin Exp Immunol ; 166(1): 55-63, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21762125

RESUMO

Activation of the oxidative burst and failure of CD4(+) CD25(+) cell regulation have been implicated in idiopathic nephrotic syndrome (iNS). The intimate mechanism is, however, unknown and requires specifically focused studies. We investigated reactive oxygen species (ROS) generation [di-chlorofluorescein-diacetate (DCFDA)] fluorescence assay and the regulatory adenosine 5'-triphosphate (ATP) pathways in the blood of 41 children with iNS, utilizing several agonists and antagonists of nucleotide/nucleoside receptors, including the addition of soluble apyrase. The CD4(+) CD25(+) CD39(+) /CD73(+) expression was determined in vivo in parallel during disease activity. Overall, we found that the percentage of CD39(+) CD4(+) CD25(+) was reduced markedly in iNS by 80% (3·43±0·04% versus 13·14±0·07% of total lymphocytes, P<0·001). In these patients, reactive oxygen species (ROS) generation by polymorphonuclear neutrophils (PMN) at rest was a function of apyrase (CD39) expressed by CD4(+) CD25(+) , with higher rates in patients with very low CD39(+) CD4(+) CD25(+) levels (<7·5%). Addition of apyrase reduced ROS generation by 40% in both iNS and controls and was mainly effective in patients. The quota of ROS surviving ATP elimination was higher still in iNS. In vitro studies to limit ROS generation with adenosine analogues (2'-chloroadenosine and 5'-N-ethylcarboxamidoadenosine) produced minor effects. At variance, antagonizing ATP efflux with carbenoxolone or by antagonizing ATP effects (Brilliant Blue G, KN62 and A437089) reduced ROS generation comparable to apyrase. These results confirm a key role of ATP in the regulation of innate immunity and minimize the effect of adenosine. Decreased CD39(+) CD4(+) CD25(+) expression in iNS highlights an impairment of ATP degradation in this pathology. However, high ROS surviving ATP consumption implies a major role of other regulatory pathways.


Assuntos
Trifosfato de Adenosina/antagonistas & inibidores , Apirase/imunologia , Imunidade Inata , Nefrose Lipoide/imunologia , Síndrome Nefrótica/congênito , Neutrófilos/metabolismo , Receptores Purinérgicos P1/metabolismo , Receptores Purinérgicos P2/metabolismo , Linfócitos T Reguladores/metabolismo , Trifosfato de Adenosina/metabolismo , Adenosina-5'-(N-etilcarboxamida)/farmacologia , Antígenos CD/biossíntese , Antígenos CD/imunologia , Apirase/metabolismo , Apirase/farmacologia , Contagem de Linfócito CD4 , Células Cultivadas , Criança , Pré-Escolar , Feminino , Citometria de Fluxo , Fluoresceínas/análise , Humanos , Imunidade Inata/efeitos dos fármacos , Masculino , Nefrose Lipoide/metabolismo , Nefrose Lipoide/patologia , Síndrome Nefrótica/imunologia , Síndrome Nefrótica/metabolismo , Síndrome Nefrótica/patologia , Neutrófilos/imunologia , Neutrófilos/patologia , Agonistas do Receptor Purinérgico P1/farmacologia , Antagonistas de Receptores Purinérgicos P1/farmacologia , Espécies Reativas de Oxigênio/metabolismo , Receptores Purinérgicos P1/imunologia , Receptores Purinérgicos P2/imunologia , Explosão Respiratória/efeitos dos fármacos , Explosão Respiratória/imunologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA